India to United States: Arishta Export Trade Route

To import finished pharmaceutical formulations containing Arishta into the United States, compliance with the U.S. Food and Drug Administration (FDA) regulations is mandatory. All foreign drug establishments must register with the FDA and list all drug products intended for commercial distribution in the U.S. This registration and listing must be completed electronically through the FDA's Electronic Drug Registration and Listing System (eDRLS).

Each imported drug product must have an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) to be legally marketed in the U.S. The application should be submitted in the Common Technical Document (CTD) or electronic CTD (eCTD) format. The FDA's review process for NDAs and ANDAs typically takes 10 months for standard applications and 6 months for priority reviews. Application fees are updated annually; for the fiscal year 2026, the NDA fee is $2,875,842, and the ANDA fee is $196,868.

Indian manufacturing facilities producing these formulations must comply with the FDA's Current Good Manufacturing Practice (cGMP) regulations. The FDA conducts routine inspections of foreign facilities to ensure compliance. Non-compliance can result in import alerts, detentions, or refusal of admission of products into the U.S.

Indian exporters of Arishta formulations must adhere to the FDA's cGMP standards to ensure product quality and safety. Facilities must be prepared for FDA inspections, which assess compliance with these standards. As of March 2026, several Indian pharmaceutical facilities have received FDA approval, indicating compliance with cGMP requirements.

Recent FDA inspections have identified compliance issues in some Indian facilities. For instance, in December 2025, the FDA issued a warning letter to an Indian manufacturer for significant cGMP violations, including inadequate quality control procedures and failure to maintain proper records. Such actions underscore the importance of maintaining stringent quality standards to avoid regulatory repercussions.

In January 2024, India's Ministry of Health revised its Good Manufacturing Practice (GMP) regulations to align more closely with global standards, particularly those of the World Health Organization (WHO). These revisions aim to enhance the quality of pharmaceutical products and facilitate smoother exports to markets like the United States.

In August 2024, the FDA's India Office addressed the regulation of herbal and Ayurvedic products, emphasizing the need for compliance with U.S. standards to ensure product safety and efficacy. This initiative reflects the FDA's commitment to overseeing the quality of imported traditional medicines.

Additionally, in October 2023, the FDA highlighted India's significant role as a global pharmaceutical supplier and the associated responsibility to maintain high-quality manufacturing practices. This acknowledgment underscores the importance of regulatory compliance for Indian exporters aiming to access the U.S. market.

These developments indicate a concerted effort by both Indian and U.S. regulatory bodies to ensure the quality and safety of pharmaceutical products in international trade.

Arishta formulations are integral to Ayurveda, a traditional system of medicine that has been gaining traction in the United States. In 2024, the U.S. Ayurveda market generated revenue of $1,542.7 million and is projected to reach $3,952.4 million by 2030, reflecting a compound annual growth rate (CAGR) of 17% from 2025 to 2030. This growth is driven by increasing consumer interest in natural and holistic health solutions.

The demand for Arishta formulations is influenced by factors such as the prevalence of chronic diseases, rising healthcare expenditures, and an aging population seeking alternative therapies. While specific data on the domestic production of Arishta formulations in the United States is limited, the import data indicates a modest volume of imports from India, suggesting that domestic manufacturing may not fully meet the growing demand.

Under HS code 30049011, the United States maintains a 0% MFN import duty rate for finished pharmaceutical formulations, including those containing Arishta. This duty-free status facilitates the importation of such products without additional tariff burdens. There are no specific Free Trade Agreements (FTAs) between India and the United States that further affect pharmaceutical tariffs, nor are there any anti-dumping duties imposed on these imports.

India is a primary supplier of Arishta formulations to the United States, accounting for 2.7% of India's total Arishta formulation exports, valued at $1.4 million. The trade data indicates that 20 Indian manufacturers/exporters are involved in this trade route, with 129 shipments recorded. The top exporters include Taneet Foods Private Limited, Bharath Vaidyasala, B N Y Naturals, Sandu Pharmaceuticals Limited, and Kerala Ayurveda Limited.

While specific data on other countries supplying Arishta formulations to the United States is not readily available, India's established position as a major exporter of Ayurvedic products suggests it holds a significant share of the market. Pricing comparisons between Indian suppliers and competitors from regions such as China or the European Union are not specified in the available data. However, India's competitive advantage likely stems from its extensive experience in Ayurvedic medicine production and cost-effective manufacturing processes.

By adhering to this comprehensive supplier qualification framework, United States companies can mitigate risks and ensure the quality and compliance of Arishta formulations sourced from Indian manufacturers.